Related Experiment Video

Updated: Jun 21, 2026

A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

Gallic acid protects RINm5F beta-cells from glucolipotoxicity by its antiapoptotic and insulin-secretagogue actions

Zaheer Sameermahmood1, Lenin Raji, Thangavel Saravanan

  • 1Department of Cell and Molecular Biology, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India 600086.

Phytotherapy Research : PTR
|July 18, 2009
PubMed

Insights

Gallic acid protects beta-cells from glucolipotoxicity-induced apoptosis, a key factor in Type 2 diabetes. This compound also enhances insulin secretion and PDX-1/insulin gene expression, suggesting novel therapeutic potential.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Endocrinology

Background:

  • Type 2 diabetes is characterized by pancreatic beta-cell dysfunction.
  • Glucolipotoxicity contributes to beta-cell apoptosis and impaired insulin secretion.
  • Gallic acid exhibits antioxidant, anti-inflammatory, and cytoprotective properties.

Purpose of the Study:

  • To investigate the protective effects of gallic acid against glucolipotoxicity in RINm5F beta-cells.
  • To explore the mechanisms underlying gallic acid's potential protective actions.
  • To assess gallic acid's impact on insulin secretion and gene expression.

Main Methods:

  • RINm5F beta-cells were exposed to high glucose and/or palmitate with or without gallic acid.
  • Assays included comet assay for DNA damage, Western blot for apoptosis markers (caspase-3, Bcl-2), and RT-PCR for gene expression (PDX-1, insulin, UCP-2).
  • NF-kappaB signaling was analyzed using EMSA, immunofluorescence, and Western blot.

Main Results:

  • Glucolipotoxicity induced DNA damage, apoptosis, and NF-kappaB activation in beta-cells.
  • Gallic acid significantly protected beta-cells against these glucolipotoxicity-induced detrimental effects.
  • Gallic acid dose-dependently increased insulin secretion and upregulated PDX-1 and insulin mRNA expression.

Conclusions:

  • Gallic acid confers protection against glucolipotoxicity-induced beta-cell apoptosis.
  • Gallic acid exhibits insulin-secretagogue and transcriptional regulatory effects on beta-cells.
  • These findings suggest a novel mechanism for gallic acid's therapeutic potential in Type 2 diabetes.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...